Basic information Mechanism of action Current clinical trials Study in vivo References Safety Related Supplier
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Cell Cycle >  CDK inhibitors >  LY2835219

LY2835219

Basic information Mechanism of action Current clinical trials Study in vivo References Safety Related Supplier
LY2835219 Basic information
LY2835219 Chemical Properties
LY2835219 Usage And Synthesis
  • Mechanism of actionMany human tumors acquire alterations, which can lead to the activation of cyclin-dependent kinases (CDKs)—CDK4 and CDK6. These alterations include mutations that directly activate CDK4 and CDK6, gene amplifications, which increase expression of various protein activators such as cyclin D, as well as genetic losses, which reduce expression of protein inhibitors such as p16.
    Abemaciclib(previously known as LY2835219) specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
  • Current clinical trialsAbemaciclib(LY2835219) is being investigated in clinical trials in patients with breast cancer, non-small cell lung cancer, and pancreatic cancer, including a combination clinical trial in immuno-oncology.
    As of early 2016 Abemaciclib is involved in 3 Phase III clinical trials:
    The JUNIPER Study is comparing Abemaciclib against Erlotinib in patients with stage IV Non-small-cell lung carcinoma.
    The MONARCH 2 study is investigating the effectiveness of Abemaciclib in combination with Fulvestrant for women with breast cancer. It is due to end in Feb 2017.
    The MONARCH 3 study is investigating the effectiveness of Abemaciclib, plus either anastrozole or letrozole, as a first-line treatment for women with breast cancer. The trail is expected to end in June 2017.
  • Study in vivoThe dose percentage of LY2835219-MsOH treating brain was 0.5-3.9%. LY2835219-MsOH could treat subcutaneous and intracranial glioma models (U87MG), inhibiting tumor growth, and the effect is dose-dependent, whether alone or in combination with mozolomide.
  • Referenceshttp://www.lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/overview
    https://en.wikipedia.org/wiki/Abemaciclib
    https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=706364
  • UsesN-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine is an CDK4/6 protein kinase inhibitor with potential antitumor effects.
  • UsesLY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively). Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.[Cayman Chemical]
  • UsesN-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine is an CDK4/6 protein kinase inhibitor with potential antitumor effects.
  • Enzyme inhibitorThis oral cell cycle inhibitor (FWfree-base = 506.61 g/mol; FWmesylate-salt = 602.70 g/mol; CAS 1231930-82-7 (mesylate salt)), also known as LY2835219 and N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5- fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2- pyrimidinamine, targets the cyclin-dependent kinase CDK4, or cyclin D1 (IC50 = 2 nM) and CDK6, or cyclin D3 (IC50 = 6 nM), inhibiting retinoblastoma (Rb) protein phosphorylation in early G1, thereby arresting the cell cycle in the G1, suppressing DNA synthesis, and inhibiting cancer cell growth. LY2835219 inhibits activation of AKT and ERK, but not mTOR.
LY2835219(1231930-82-7)Related Product Information
LY2835219SupplierMore
  • Company Name:Hubei Chuangliankangcheng Pharmaceutical Co., Ltd. Gold
  • Tel:18164111589 027-65388397
  • Email:3321478047@qq.com
  • Products Intro:Product Name:LY2835219
    CAS:1231930-82-7
    Purity:99 Package:1g.10g.100g.500g,1kg
  •  
  • Company Name:Hunan Hezhong Pharmaceutical Co., Ltd. Gold
  • Tel:027-87614241 QQ 3310618156
  • Email:3310618156@qq.com
  • Products Intro:CAS:1231930-82-7
    Purity:99% Package:1g,10g,100g,1kg
  •  
  • Company Name:Jinan Winwind Biological Technology Co., Ltd Gold
  • Tel:15153166971
  • Email:win-wind@hotmail.com;
  • Products Intro:Product Name:N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine,methanesulfonic acid
    CAS:1231930-82-7
    Purity:99 Package:1KG;500g;100g;50g;10g
  •  
  • Company Name:Shanghai Boyle Chemical Co., Ltd.
  • Tel:
  • Email:sales@boylechem.com
  • Products Intro:Product Name:LY2835219 mesylate
    CAS:1231930-82-7
  •  
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Email:jkinfo@jkchemical.com;market6@jkchemical.com
  • Products Intro:Product Name:N-[5-[(4-Ethyl-1-piperazinyl)Methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-Methyl-1-(1-Methylethyl)-1H-benziMidazol-6-yl]-2-pyriMidinaMine Methanesulfonate
    CAS:1231930-82-7
    Package:2.5Mg,25Mg
  •